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B-cell chronic lymphocytic leukaemia (B-CLL) is characterised by the progressive accumulation of monoclonal CD5
þ B cells. In a
previous study, we have analysed the expression profile of apoptosis-regulating genes using a cDNA-based microarray and found
overexpression of the antiapoptotic bcl-2 family member, bfl-1, in B-CLL cells with an apoptosis-resistant phenotype. In this study,
bfl-1 mRNA levels have been determined by competitive PCR in an extended population of B-CLL patients to characterise its role in
disease progression and development of chemoresistance. bfl-1 levels were significantly higher in patients with no response (NR) to
last chemotherapy than in patients responding (partial response (PR)) to last chemotherapy (Po0.05) and in patients who had not
required treatment (Po0.05). We found no correlation between bfl-1 mRNA levels and disease progression, IGHV mutational status
or other clinical parameters. In addition, bfl-1 mRNA levels were inversely correlated with apoptotic response to in vitro fludarabine
treatment of B-CLL cells. Specific downregulation of bfl-1 using siRNA induced apoptosis in resistant cells. Our data suggest that bfl-1
contributes to chemoresistance and might be a therapeutic target in B-CLL.
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B-cell chronic lymphocytic leukaemia (B-CLL) is characterised by
the accumulation of a clonal population of malignant CD5
þ B cells
in the blood, bone marrow, lymph nodes and spleen (Jurlander,
1997). Patients with B-CLL follow a highly variable clinical course.
Some patients remain stable for a long time, without the need for
therapy, while others progress rapidly to a more advanced disease
and die despite aggressive treatment (O’Brien et al, 1995).
Although this disease is still incurable, responses are observed
with alkylating agents or nucleoside analogues. However, despite
initial responses to therapy, relapse and eventual chemotherapy
resistance usually occur in B-CLL patients.
B-CLL cells have a low proliferative rate and a prolonged life
span, suggesting that their accumulation in vivo results from
defects in the apoptotic process (Hamblin and Oscier, 1997). The
underlying defects in apoptosis in B-CLL cells also contribute to
chemotherapy resistance. The mechanisms behind the resistance
of B-CLL to apoptosis are largely still undefined, but previous
studies support a regulatory role of Bcl-2 family of apoptosis-
regulatory proteins, such as Bcl-2/Bax and Mcl-1, in the survival of
B-CLL cells (Aguilar-Santelises et al, 1996; Osorio et al, 1997;
Kitada et al, 1998; Morales et al, 2005).
Bfl-1 is an antiapoptotic member of the Bcl-2 family shown to
protect from apoptosis induced by a variety of apoptotic stimuli
such as death-receptor ligation (Werner et al, 2002), p53 over-
expression (D’Sa-Eipper et al, 1996), DNA-damaging agents (Wang
et al, 1999) and serum deprivation (Zhang et al, 2000). Recently, it
was reported that Bfl-1 can also promote apoptosis after TNF
receptor activation in pro-B cells, dependent on proteolytic
processing of Bfl-1 (Kucharczak et al, 2005). This work suggests
that Bfl-1 may exert different effects depending on the nature of the
death-inducing stimulus. In humans, bfl-1 expression is found in
various types of haematopoietic cells in the bone marrow, in
germinal centres of peripheral lymphoid organs, haematopoietic
cells of fetal liver (Jung-Ha et al, 1998), endothelial cells and in
smooth muscle cells (Karsan et al, 1996). bfl-1 is a direct
transcriptional target of NF-kB( Z o n get al, 1999), and is inducible
by inflammatory stimuli in various cell types (Karsan et al, 1996;
Moreb and Schweder et al, 1997). In B lymphocyte-derived cell lines
and in primary B cells bfl-1 is induced by CD40 ligation and has
been shown to protect from apoptosis triggered by ligation of the B-
cell receptor or Fas (Kuss et al, 1999; Craxton et al,2 0 0 0 ) .I nB - C L L
bfl-1 is inducible by B-cell receptor crosslinking and CD40L (Bernal
et al, 2001; Kater et al, 2004). bfl-1 has also been implicated in
CD40L mediated resistance towards fludarabine-induced apoptosis
in B-CLL cells (Kater et al, 2004). Inhibition of constitutive and
inducible NF-kB using NF-kB inhibitors induced apoptosis
and enhances fludarabine effects on B-CLL associated with down-
regulation of bfl-1 and other antiapoptotic genes (Horie et al, 2006).
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sIn a previous study, using a cDNA-based microarray approach to
characterise expression of apoptosis-regulating genes in B-CLL, we
found the antiapoptotic bcl-2 family member bfl-1 as the most
discriminating gene between untreated patients whose leukaemic
cells were sensitive to in vitro fludarabine-induced apoptosis and
chemotherapy refractory patients with in vitro fludarabine-resistant
leukaemic cells (Morales et al, 2005). In the present study, bfl-1
mRNA levels have been quantified by competitive PCR in an
extended population of B-CLL patients to characterise its role in
disease progression and development of chemoresistance. We show a
correlation between high bfl-1 expression and chemotherapy
refractoriness and resistant to in vitro fludarbine-induced apoptosis.
In addition, by siRNA-mediated targeting we demonstrate that
downmodulation of bfl-1 induces apoptosis in resistant B-CLL cells.
MATERIALS AND METHODS
Reagents
Primers for PCR amplification were synthesised by CyberGene AB
(Huddinge, Sweden). Trizol Reagent, oligo(dT)15 primer and
MMLV reverse transcriptase were from Invitrogen (Carlsbad,
CA, USA). Fluorescein isothiocyanate (FITC)-F(ab0)2 fragment of
rabbit anti-human IgM, phycoerythrin (PE)-conjugated anti-CD25,
anti-CD3-PE, anti-CD5-FITC and anti-CD20-PE were from Dako-
cytomation A/S (Copenhagen, Denmark). Anti-CD38-PE, allophy-
cocyanin (APC) conjugated anti-CD19 and IgG1-FITC/IgG2a-PE
simultest were from Becton Dickinson (Mountain View, CA, USA).
Fludarabine and chlorambucil were from Sigma Chemicals (St
Louis, MO, USA).
Patients
The study was approved by the Karolinska Institutet Ethics
Committee and informed consent was obtained from all patients.
No antitumor therapy was allowed for at least 1 month prior to
sample acquisition. All patients had a confirmed diagnosis of
B-CLL and were staged according to Rai et al (1975). Patients
were considered to have a progressive disease, according to a
modification of the criteria by the National Cancer Institute
Committee (Silver et al, 1978), if there was progression during
the preceding 3 months in disease-related anaemia (and Hb
o100gl
 1), in thrombocytopaenia (and platelet count
o100 10
9l
 1) and/or in spleen/liver/lymph node size (evaluated
by both clinical examination and computer tomography of the
abdomen) and/or in more than a doubling of the blood
lymphocyte counts and/or appearance of constitutional symptoms.
Response to chemotherapy treatment was classified as no
response, partial response or complete response (NR, PR or CR)
according to the NCI–WG criteria (Cheson et al, 1996); (Table 1).
Cell separation
Leukaemic B cells were isolated from heparinised blood taken
from B-CLL patients. Lymphocytes were obtained after carbonyl
iron treatment and Lymphoprep (Nycomed, Oslo, Norway)
centrifugation, and T cells were depleted by rosetting with sheep
erythrocytes. Isolated cells were kept frozen in aliquots. Isolated
non-rosetting, leukaemic B cells contained less than 2.0% CD3
þ
cells as estimated by flow cytometry.
Cell phenotype
Isolated cells from all B-CLL patients were phenotyped by
immunofluorescence and flow cytometry. Cells (1 10
6) were
incubated for 30min at 41C with anti-CD5-FITC, anti-CD19-APC,
anti-CD25-PE, anti-CD20-PE, anti-CD38-PE, anti-CD3-PE or FITC-
F(ab0)2 anti-human IgM. FITC/PE-conjugated simultest was used
as control. Forward and side-scatter gates were set to exclude dead
cells. All samples were analysed in a Becton Dickinson FACScan
system equipped with an argon laser, using 10000 cells for each
determination.
Cell cultures
B-CLL cells were re-suspended in RPMI-1640 medium supple-
mented with 2mM glutamine, 100IUml
 1 penicillin, 100mgml
 1
streptomycin and 0.5% bovine serum albumin (BSA fraction-V).
Cells (0.5 10
6ml
 1) were incubated in 96-well plates in medium
alone (spontaneous apoptosis) or in the presence of fludarabine
(5mM) or chlorambucil (40mM) for 48h to evaluate apoptotic
response. The NIH3T3 mouse fibroblast cell line transfected with
human CD40L were cultured in RPMI-1640 medium supplemented
with 10% fetal bovine serum (FBS), 2mM glutamine, 100IUml
 1
penicillin, 100mgml
 1 streptomycin in 24-well plates (2 10
5 cells
per well), and incubated overnight to adhere before addition of
siRNA-transfected B-CLL cells.
Apoptosis
Percentage of apoptotic cells was determined by AnnexinV
staining. Cells were washed with PBS and incubated 10min in
100ml of binding buffer (10mM HEPES/NaOH, pH 7.4, 140mM
NaCl, 5mM CaCl2) containing AnnexinV-Fluos solution (Roche
Molecular Biochemicals, Mannheim, Germany) and 2mgml
 1
propidium iodide (Sigma Chemicals). Cells were analysed with a
FACScan (Becton Dickinson). For fludarabine- and chlorambucil-
induced apoptosis percentages of specific apoptosis were calcu-
lated as (apoptosis in drug culture spontaneous apoptosis)/
(100 spontaneous apoptosis) 100%.
Competitive PCR
Total RNA was isolated from purified B-CLL cells using Trizol
reagent. Three micrograms of total RNA was denatured and
reverse transcribed using oligo-(dT)15 primers. Thereafter, 1mlo f
cDNA was amplified in a 20ml PCR mixture. Two microlitres of
serial dilutions of competitor fragments, with different lengths but
using the same primers as the target DNA, was added to the
reaction. G3PDH competitor (MIMIC, 630bp) was from Clontech
(Mountain View, CA, USA) and the bfl-1 competitor (446bp) was
from Gentaur Molecular Products (Brussels, Belgium). Competitor
for bcl-2 (230bp) was built using composite primers and an
exogenous DNA fragment (BamHI–EcoRI restriction fragment
from v-erb). Cycling conditions for bfl-1 and bcl-2 were 30 cycles
of 1min at 941C, 1min at 601C and 2min at 721C and for G3PDH
35 cycles of 1min at 941C, 1min at 601C, and 1min at 721C. The
samples were then resolved on a 2% agarose gel with 1mgml
 1 of
ethidium bromide and photographed. Densitometric analysis was
performed using Quantity One (BioRad, Hercules, CA, USA).
Ratios of the intensity of the relevant PCR product pairs were
plotted against the concentration of the competitor DNA used in a
logarithmic plot. The point of intersection in the curve, where the
amounts of target and competitor are equal was used to determine
the amount of cDNA in the sample. The primers are as follows:
sense bfl-1,5 0-GGCAGAAGATGACAGACTGTGAA-30; antisense
bfl-1,5 0-TGGTCAACAGTATTGCTTCAGGA-30 (539bp); sense
bcl-2,5 0-CGACGACTTCTCCCGCCGCTACCGC-30; antisense bcl-2,
50-CCGCATGCTGGGGCCGTACAGTTCC-30 (319bp); sense
G3PDH,5 0-TGAAGGTCGGAGTCAACGGATTTGGT-30; antisense
G3PDH,5 0-CATGTGGGCCATGAGGTCCACCAC-30 (983bp).
siRNA treatment of B-CLL cells
Transfection of B-CLL cells was performed according to a modified
and optimised TransIT-TKO
s Transfection Reagent (Mirius
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sTable 1 Clinical characteristics, apoptotic response, mutational status and genetic alterations of included patients
CLL
Sex/
age
Rai
stage Progression
Mo since
diagnosis
Previous
therapy
a
Blood lymphocyte count
( 10
9l
 1)
Fludarabine-specific
apoptosis (%)
CLB-specific
apoptosis (%)
Response to
therapy FISH code
b
IGHV mutational status
c/
IGHV3-21
d
1 M/73 0 — 53 — 40 24.0 59.1 — del(13q) Mutated (high)
2 M/66 0 — 68 — 20 90.4 98.4 — ND Mutated (high)
3 F/61 0 — 135 — 78 82.0 84.6 — del(13q) Mutated (high, NF)
4 M/67 0 — 90 — 22 88.1 94.9 — Normal ND
5 M/86 0 — 39 — 55 80.4 26.4 — del(11q) Mutated (high)
6 F/76 0 — 47 — 62 75.7 59.4 — Normal Mutated (high)
7 F/81 0 — 179 — 104 89.0 89.1 — trisomy 12 Mutated (low)
8 M/69 0 — 78 — 25 82.6 45.8 — del(13q) Mutated (low)
9 M/69 0 — 26 — 74 42.5 67.6 — ND Unmutated
10 M/58 0 — 30 — 35 88.4 ND — ND Mutated (high)
11 M/59 0 — 76 — 27 13.4 18.7 — del(13q) Mutated (high, NF)
12 M/76 0 — 32 — 147 71.5 78.3 — del(11q) Mutated (high)
13 M/71 I — 10 — 30 79.8 ND — ND Unmutated
14 F/70 I — — 112 73.6 72.4 — del(13q) Mutated (low)
15 F/73 I — 77 — 27 85.1 96.3 — ND Mutated (high, NF)
16 M/68 I — 5 — 42 76.9 39.1 — del(11q) Unmutated
17 M/66 II — 72 — 41 71.2 ND — ND Mutated (high)
18 F/79 II — 68 CLB (9) 48 44.9 79.4 NR del(13q) Mutated (high)
19 M/85 III — 150 CLB (13) 138 68.5 55.9 PR del(11q) Mutated (low)
20 F/77 0 + 122 CLB (6) 38 65.3 50.9 PR trisomy 12 Mutated (low) IGHV3-21
21 F/79 I + 53 CLB (6) 61 69.0 81.2 PR del(13q) Mutated (low)
22 F/69 II + 58 CLB (1) 54 7.4 ND NR del(13q) Mutated (low)
23 M/86 II + 29 CLB (5) 117 82.8 55.7 PR del(13q) Unmutated IGHV3-21
24 M/65 II + 29 CLB (1) 329 21.8  5.5 NR Normal Mutated (low)
25 M/70 II + 96 CLB (72) 66 11.7 13.8 NR del(17p)-
borderline
Unmutated
26 M/61 II + 61 FLUD (38) 53 40.6 32.4 PR del(17p) Mutated (high)
27 F/87 II + 260 COP (12) 176 18.6  1.3 NR Inconclusive Mutated (high, NF) IGHV3-21
28 F/80 II + 69 CLB (8) 208 85.8 18.0 PR trisomy 12 Mutated (high)
29 M/81 II + 24 CLB (5) 200 66.4 19.7 PR del(11q) (&
trisomy 12)
Mutated (low) IGHV3-21
30 M/64 III + 23 FLUD (11) 354 32.3  2.5 NR del(13q) Mutated (low, NF)
31 M/67 III + 142 MIME (7) 304 3.5 7.1 NR del(17p) Unmutated
32 F/69 III + 239 FLUD (11) 198 7.9 5.3 NR del(13q) Mutated (high)
33 F/80 III + 216 CLB (1) 176 16.4 26.3 NR ND Unmutated
34 F/52 IV + 116 CLB (19) 69 92.5 96.9 NR trisomy 12 Mutated (high)
35 M/77 IV + 169 CLB (3) 488 16.7 5.2 NR del(17p) Unmutated
36 M/55 IV + 96 MIME (3) 68 12.9 18.9 NR ND Unmutated
37 F/64 IV + 38 CLB (11) 27 65.8 39.9 NR ND Unmutated IGHV3-21
CLB¼chlorambucil; COP¼cyclophosphamide, vincristine, prednisone; CR¼complete response; FLUD¼fludarabine; MIME¼mitoguanozone, ifosfamide, methotrexate, etoposide; ND¼not determined; NF¼non-functional;
NR¼no response; PR¼partial response.
aLast therapy before sample and months since last treatment in parentheses. .
bCoding after FISH analysis based on clinical relevance. Del(13q) corresponds to single aberration.
cUnmutated
X98% homology, mutated o 98% homology, low: 2–5% mutations, high: 45% mutations.
dIGHV gene usage was analysed in all patients, only IGHV3-21 is noted separately because of the clinical importance, regardless mutational
status.
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Translational TherapeuticsCorporation, Madison, WI, USA) protocol for adherent cells. bfl-1-
specific siRNA (Dharmacon SMARTpool
s siRNA (proprietary
target sequence)) and two nonspecific, scrambled siRNA, pooled
together as ‘control siRNA’ were ordered from Dharmacon
Research Inc. (Lafayett, CO, USA). B-CLL cells (2 10
6) suspended
in 200ml AIM V cell culture medium supplemented with 5% FBS,
100IUml
 1 penicillin and 100mgml
 1 streptomycin were seeded
in each well in 48-well plates. For each well 9ml TransIT-TKO
s
and 80pmol siRNA diluted in Opti-MEM
s culture medium were
added or cells were left untransfected. Six hours after transfection,
cells were transferred to hCD40L-expressing mouse fibroblast
cultures. At 24 and 48h after transfection apoptotic response was
determined by AnnexinV staining and mRNA expression was
analysed by RT–PCR.
RT–PCR
Total RNA was isolated using RNeasy Mini Kit (Qiagen, Hilden,
Germany), and reverse transcribed using N6 and oligo-(dT)18
primers. Thereafter, 1ml of cDNA was amplified in a 20ml PCR
mixture. Cycling conditions were 30 cycles of 30s at 941C, 30s at
601C and 30s at 721C for RPLP0 and 24 cycles of 1min at 941C,
1min at 601C and 2min at 721C for bfl-1. Primers for bfl-1 are as
for competitive PCR, and for RPLP0 sense 50-TTAAACCC
CCTCGTGGCAATC-30; antisense 50-CCAACTTCCCCCGCATAT
GA-30 (293bp).
Cytogenetic analysis
To detect the prognostically relevant chromosomal aberrations
del(13q), del(11q), trisomy 12 and del(17p), FISH analysis was
performed using commercial probes from Abbot Vysis (Stuttgart,
Germany) as described previously (Do ¨hner et al, 2000). Two-
hundred interphase nuclei were analysed for each probe and
sample. Samples showing between 10 and 15% cells with a
particular aberration were considered as ‘borderline’.
IGHV gene analysis
Genomic DNA was prepared from leukaemia cells using the
QIAamp DNA Mini Kit from Qiagen (Valencia, CA, USA). PCR
amplification of the IGH gene rearrangements was performed with
either genomic DNA or cDNA using family-specific IGHV
(framework region 1) primers together with one consensus IGHJ
primer as described previously. The PCR conditions for the IGH
analysis was as outlined earlier with minor modifications (Kuppers
et al, 1993; Willems et al, 2000; van Dongen et al, 2003). The PCR
products were either direct sequenced (35 cases) using the Big Dye
Terminator Cycle Sequencing Reaction Kit (Applied Biosystems,
Foster City, CA, USA) or subcloning of the PCR product (three
cases) was performed using the TOPO TA Cloning Kit For
Sequencing (Invitrogen, Paisley, UK). A minimum of six colonies
were subsequently sequenced from each cloned sample. The
sequences were analysed using an automated DNA sequencer (ABI
3700; Applied Biosystems).
The obtained IG sequences were submitted to different IG
sequence databases, International ImMunoGeneTics (IMGT),
IgBLAST (National Centre for Biotechnology Information, USA)
and JOINSOLVER
s (http://joinsolver.niams.nih.gov), and aligned
to the most homologous germline IGHV, IGHD and IGHJ genes.
Using the classical IGHV homology cutoff value of 98%, cases were
divided in unmutated (X98% homology to the corresponding
germline gene) or mutated (o98% homology) (Table 1). Cases
with less than 98% homology only in a non-functional rearrange-
ment were also considered mutated. At least seven nucleotides
(allowing one mutation) aligned to the most homologous germline
gene were required to identify the IGHD gene segment. The
mutated cases were also classified in ‘low mutated’ (between 97.9
and 95% of homology) or ‘high mutated’ (o95% homology).
IGHV gene usage was determined in all patients and patients with
IGHV3-21 usage were noted separately because of the clinical
importance of this group (poor prognosis), regardless their
mutational status (Tobin et al, 2002).
Statistical analysis
Estimation of statistical differences between groups was carried
out using the Kruskal–Wallis test for comparison between three or
more groups, and the Mann–Whitney U-test for comparison
between two unpaired groups.
RESULTS
High expression of bfl-1 correlates with chemotherapy
refractoriness of B-CLL
bfl-1 mRNA levels were determined by competitive PCR in 37
B-CLL patients, whose clinical characteristics are shown in Table 1,
and correlated to in vivo response to the last chemotherapy prior
to date of sampling (Figure 1A). Twenty of the 37 included patients
were treated previously. Last chemotherapy and clinical responses
are shown in Table 1. Expression levels of bcl-2 were also
determined by competitive PCR and are shown in Figure 1B. bfl-1
expression levels were significantly higher in the NR group
(mean¼1.77, s.d.¼1) compared to the PR group (mean¼0.74,
s.d.¼0.48, Po0.05) and compared to the non-treated group
(mean¼1.0, s.d.¼0.89, Po0.05). Since most of the treated
patients received CLB as the last chemotherapy, the analysis was
repeated including only untreated and the 14 CLB-treated patients
and equal statistic differences in bfl-1 expression were found as
compared to the analysis including all the treated patients (NR vs
PR Po0.05 and NR vs untreated Po0.05, data not shown). For
bcl-2 there was a significant higher expression in the NR group
(mean¼1.06, s.d.¼0.54) compared to the PR group (mean¼0.52,
s.d.¼0.34, Po0.05), while the untreated group had levels in the
same range as the NR group (mean¼1.24, s.d.¼0.59) (Figure 1B).
However, bcl-2 expression in the untreated group was significantly
higher than in the PR group (Po0.01). If only CLB-treated patients
are included in the analysis, the difference in bcl-2 expression
between NR and PR does not reach statistical significance (data
not shown). High expression was seen of at least one of the genes,
in a majority (10 out of 13) of cases in the NR group, comparing
both genes together in the treated patients while the expression of
both were in general low in the PR group (Figure 1C).
High bfl-1 levels correlate with resistance to in vitro
fludarabine-induced apoptosis
Leukaemic cells from the patients included were tested for in vitro
fludarabine- and chlorambucil-induced as well as spontaneous
apoptosis. Cells were cultured in the presence or absence of drug
(5mM fludarabine or 40mM chlorambucil) for 48h and apoptosis
quantified by AnnexinV staining. Specific drug-induced apoptosis
was calculated after subtraction of spontaneous apoptosis as
described in Materials and Methods section (Table 1). An arbitrary
cutoff of 25% specific apoptosis was used to consider patient as
resistant or sensitive to in vitro drug-induced apoptosis, based on
our experience with in vitro cultured B-CLL cells. Fludarabine-
resistant cells expressed significantly higher levels of bfl-1 mRNA
compared to sensitive cells (mean¼1.87, s.d.¼0.99 and
mean¼0.91, s.d.¼0.81, respectively, Po0.01, Figure 2). No
correlation between bfl-1 levels and spontaneous apoptosis or
chlorambucil-induced apoptosis was found (data not shown).
When only the untreated patients (n¼17, Table 1) were
considered, we observed that two samples were resistant to
fludarabine and had very high levels of bfl-1, while samples from
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levels of bfl-1 mRNA (Po0.05, data not shown). There was no
significant correlation between bfl-1 expression and apoptotic
response to fludarabine in the treated group (data not shown). No
difference in expression of bcl-2 mRNA was detected between cells
that were either sensitive or resistant to fludarabine or chlor-
ambucil treatment in vitro (data not shown). Cells from NR
patients were significantly more resistant to fludarabine than those
from PR or untreated patients (Po0.01) (data not shown).
Relationship between bfl-1 expression and disease
progression, IGHV mutational status and genetic
alterations
Next, we wanted to investigate if bfl-1 was involved in disease
progression, and thus bfl-1 mRNA expression was compared
between progressive and non-progressive patients. Although there
was a tendency to higher bfl-1 expression in progressive patients
the difference did not achieve statistical significance (data not
shown). In addition, bfl-1 expression did not correlate with
lymphocyte count, Rai stage, age, sex or CD38 expression (data not
shown).
The IGHV gene mutation status was analysed in 36 B-CLL cases
included in this study using IGHV gene family-specific PCR
amplification and nucleotide sequencing as described in Materials
and Methods section (Table 1). bfl-1 or bcl-2 mRNA expression
did not correlate with the mutational status of the patients,
independently of cutoff value (98 or 95%) and if the five cases
using the VH3-21 gene were considered as a separated group (data
not shown).
The prognostically relevant chromosomal aberrations del(11q),
trisomy 12, del(13q) and del(17p) were analysed by fluorescence
in situ hybridisation (FISH) in 28 B-CLL cases. We found three
B-CLL patients with no aberration (11) and 11 (39%) with the
good prognostic aberration 13q deletion as single aberration,
whereas the intermediate prognostic aberration trisomy 12 and the
poor prognostic aberrations 11q deletion and 17p deletion were
detected in 4 (14), 5 (18) and 4 (14%) patients, respectively. Among
the patients with 17p deletion one was considered borderline
(10–15% cells with the aberration). In one patient (3%), the FISH
data were not conclusive (Table 1). bfl-1 or bcl-2 mRNA was
significantly higher expressed in the good prognosis del(13q)/
‘normal’ group as compared to the intermediate/bad prognosis
trisomy 12/del(11q)/del(17p) group (Po0.01 and Po0.02,
respectively) (Figure 3). bfl-1 or bcl-2 mRNA expression was also
compared, within each cytogenetic group (good and intermediate/
bad prognosis), between NR and PR patients, and between
treated and untreated patients. Although this study included
too few patients to make a proper analysis and draw any
conclusions, we noted that both bfl-1 and bcl-2 levels were
higher in NR patients than in PR patients, independent of the
cytogenetic status. However, there were no differences between
treated and untreated patients within each cytogenetic group (data
not shown).
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Figure 1 Correlation between bfl-1 and bcl-2 expression and therapy requirement and outcome bfl-1 (A) and blc-2 (B) mRNA expression was
determined using competitive PCR. Results are shown as mRNA expression relative to the median of the sample population. Boxes show intraquartile range.
Whiskers correspond to the 10th and 90th percentile, and horizontal line within boxes represents the median value. Data correspond to 17 untreated
patients, 13 patients with no response (NR) to treatment and 7 with partial response (PR). bfl-1 comparison NR vs PR, Po0.05 and NR vs untreated,
Po0.05. bcl-2 comparison NR vs PR, Po0.05 and PR vs untreated, Po0.01. (C) Comparison of bfl-1 and bcl-2 mRNA expression, as determined by
competitive PCR, and therapy outcome. Data are represented as fold increase/decrease mRNA expression relative to the median of the sample population.
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ssiRNA-mediated downregulation of bfl-1 induces apoptosis
in resistant B-CLL cells
To test directly the contribution of blf-1 to apoptosis resistance in
B-CLL we targeted bfl-1 expression by specific siRNA in
fludarabine-resistant, bfl-1 high-expressing B-CLL cells (CLL-24,
CLL-32, CLL-27 and CLL-33; Figure 4). Initial experiments with
fluorescently labelled nonspecific siRNA showed efficient uptake
in B-CLL cells under the conditions used (Derkow, unpublished
observation). Downmodulation of bfl-1 mRNA was seen 24h after
transfection (Figure 4A) and expression levels did not decrease
further at 48h (not shown). At 24h apoptosis was also clearly
induced in cells transfected with bfl-1-specific siRNA but not in
cells transfected with control siRNA or in untransfected cells
(Figure 4B) and did only further increase slightly at 48h (not
shown), showing that in these resistant cases with high bfl-1
expression, bfl-1 is indeed important for the survival of the cells.
DISCUSSION
Even though the majority of symptomatic B-CLL patients respond
to initial therapy, almost all progress and develop refractory
disease given sufficient time. The underlying defects in apoptosis
in B-CLL cells presumably contribute to the chemotherapy
resistance in such patients. Here, we have shown high bfl-1 mRNA
expression in leukaemic cells from chemotherapy refractory B-CLL
patients. Several members of the Bcl-2 family of apoptosis-
regulating proteins have previously been implicated in the
deregulation of apoptosis and in chemotherapy resistance in
B-CLL (Morales et al, 2005). Higher levels of Mcl-1 have been
reported to be associated with a failure to achieve complete
remission following chemotherapy (Kitada et al, 1998). Higher
levels of Bcl-2 protein or higher Bcl-2/Bax ratios have been
associated with in vitro resistance to drug-induced apoptosis
(McConkey et al, 1996; Thomas et al, 1996). Increased Bcl-2/Bax
ratios have also been correlated to a more aggressive behaviour of
B-CLL, including progressive disease, refractoriness to chemo-
therapy, and shorter survival (Aguilar-Santelises et al, 1996,
Pepper et al, 1998). However, not all studies have identified an
association between Bcl-2 or Bax expression and chemoresistance
and/or clinical outcome in B-CLL, implying that other factors play
a role (Robertson et al, 1996; Johnston et al, 1997; Kitada et al,
1998). Using microarrays, we recently found a pattern of high
expression levels of bfl-1, bcl-2 and mcl-1 mRNAs in apoptosis-
resistant B-CLL cells (Morales et al, 2005). In our current study, we
found significantly higher expression of bfl-1 and bcl-2 in the
refractory patients. The strongest difference between non-
responding and responding patients was seen when both bfl-1
and bcl-2 were considered together, with high expression of at least
one of the genes in the refractory group compared to low
expression of both in patients that had responded to chemother-
apy. This indicates that the expression of both bfl-1 and bcl-2, and
possibly additional members of the bcl-2 family, such as mcl-1,
may give the best prediction of chemotherapy response.
Our current results do not answer if high mRNA expression
levels of bfl-1 is predictive of chemotherapy outcome or if it is a
result of resistance development. The fact that most untreated
patients had low bfl-1 levels and that the majority of the treated
patients had received several rounds of treatment, responding
initially, argues that bfl-1 expression could be increased as a result
of treatment and might contribute to resistance development. In
fact, bfl-1 has previously been implicated in chemotherapy
resistance development in model systems. Increased expression
of bfl-1 has been found in an in vivo established vinflunine-
resistant murine leukaemia cell line as well as in in vitro
established cisplatin-resistant bladder cancer cell lines compared
to their respective sensitive parental cell lines (Kruczynski et al,
2002; Kim et al, 2004). We have found that fludarabine did not
induce increased bfl-1 expression in B-CLL cells in a short-term
culture (Olsson, unpublished observation). However, most patients
had been receiving other chemotherapy regimens and the
increased bfl-1 expression could be a long-term effect or due to
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Figure 2 Correlation between bfl-1 expression and in vitro fludarabine-
induced apoptosis. Isolated B cells (0.5 10
6) from B-CLL patients (all 37
patients included in the study, Table 1) were cultured in 96-well plates in
medium alone (non-supplemented with FBS) or with fludarabine (5mM).
Apoptosis was measured after 48h of culture using AnnexinV staining and
fludarabine-specific apoptosis was calculated as described in Materials and
Methods section. Cells were considered resistant if specific fludarabine-
induced apoptosis was less than 25% (resistant, n¼11; sensitive, n¼26).
bfl-1 mRNA expression was determined before culture using competitive
PCR. Results are shown as mRNA expression relative to the median of the
sample population. Boxes show intraquartile range. Whiskers correspond
to the 10th and 90th percentile, and horizontal line within boxes represents
the median value. Comparison: resistant vs sensitive, Po0.01.
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Figure 3 Correlation between bfl-1 and bcl-2 expression and
chromosomal aberrations. The prognostically relevant chromosomal
aberrations del(13q), trisomy 12, del(11q) and del(17p) were determined
by FISH analysis in 28 B-CLL patients included in the study (Table 1).
Patients were grouped in good prognosis del(13q)/‘normal’ group (n¼14)
and intermediate/bad prognosis trisomy 12/del(11q)/del(17p) group
(n¼13). bfl-1 and blc-2 mRNA expression was determined using
competitive PCR and results are shown as mRNA expression relative to
the median of the sample population. Boxes show intraquartile range.
Whiskers correspond to the 10th and 90th percentile, and horizontal line
within boxes represents the median value. Comparison del(13q)/‘normal’
vs trisomy 12/del(11q)/del(17p) for bfl-1, Po0.01, and for bcl-2 Po0.02.
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sselective killing of cells expressing lower levels of bfl-1. Prospective
studies are warranted to resolve this question.
We did not find any correlation between high expression of bfl-1
and progressive disease or advanced stage of disease. This
indicates that at least in part different factors govern disease
progression/aggressiveness of disease and chemotherapy refrac-
toriness. Absence of somatic IGHV hypermutations has been
associated with the requirement of therapy and poor survival
(Damle et al, 1999; Hamblin et al, 1999). Although no study
investigating the impact of IGHV mutation status on the outcome
of therapy of B-CLL patients has been reported, an in vitro study
shows higher sensitivity to induction of apoptosis by several
chemotherapeutic agents in unmutated cases (A ˚leskog et al, 2004).
This, together with our results of no correlation of bfl-1 or bcl-2
antiapoptotic gene expression with the mutational status, suggest
that the difference in prognosis between B-CLL cases with
unmutated or mutated IGHV genes is not explained by the cellular
apoptosis sensitivity.
It was surprising to find a higher expression of bfl-1 mRNA in
patients with del(13q) or ‘normal’ karyotype, as compared to the
trisomy 12/del(11q)/del(17p) group. As a single cytogenetic defect,
del(13q) is a good prognosis marker, associated with longer overall
and treatment-free interval (Do ¨hner et al, 2000). However, there is
no study on the prognostic significance of del(13q) on the
response to therapy. Others have found higher bcl-2 expression in
B-CLL cells with del(13q) or normal karyotype as compared to the
bad prognosis groups del(17p), trisomy 12 or del(11q), which is in
agreement with our results (Jahrsdo ¨rfer et al, 2005). In addition,
the expression of two microRNAs, miR-15a and miR-16-1, is
inversely correlated to bcl-2 expression in B-CLL samples and they
negatively regulate bcl-2 at a post-transcriptional level (Cimmino
et al, 2005). These two microRNAs are located in the minimally
deleted region at 13q14.3, which could explain the high expression
of bcl-2 in the del(13q) group. Further studies are ongoing to
explore the relation between chromosomal aberrations and
apoptosis-regulating genes in B-CLL, as well as to determine the
predictive value of apoptosis-regulating genes for the treatment
response in good and bad prognosis cytogenetic groups.
We found a correlation between bfl-1 expression and in vitro
fludarabine-induced apoptosis, but not with spontaneous or
chlorambucil-induced apoptosis. However, bfl-1 expression
correlated with in vivo response to chlorambucil. Previously,
Mcl-1 expression was reported to correlate to in vitro chlorambucil-
induced apoptosis but not to fludarabine-induced apoptosis
(Johnston et al, 2004). Although both drugs induce apoptosis
through a mitochondria-dependent pathway, initiation of the
pathway may depend on different mechanisms, which might
be selectively counteracted by bfl-1 or mcl-1. In contrast to what
is the case for the proapoptotic bcl-2 family members, not much
is known about functional differences between individual anti-
apoptotic members of the family. Growing evidence indicates,
however, that different antiapoptotic bcl-2 family members are
counteracted specifically by different proapoptotic BH3-only
proteins activated by different signals (Chen et al, 2005; Willis
et al, 2005). Further studies are bound to find other functional
niches for other antiapoptotic bcl-2 members, which might explain
their selective protection against various apoptotic stimuli activating
the mitochondrial pathway. Our contradictory results regarding the
correlation of bfl-1 expression level with in vitro and in vivo
response to chlorambucil might also be explained by differences
in the mechanisms regulating the apoptotic process in vitro
and in vivo.
By selectively downmodulating bfl-1 using specific siRNA we
could induce apoptosis in fludarabine-resistant B-CLL cells,
showing that bfl-1 has a protective role against apoptosis in
these cells. Together with our recent finding that bfl-1 mRNA
expression levels are decreased in apoptosis-sensitive cells
during spontaneous apoptosis in vitro (Morales et al, 2005)
and the finding by Kater et al (2004) that CD40L, known to
promote survival of B-CLL cells in vivo, induces the expression of
bfl-1 in B-CLL cells, protecting them from spontaneous and
fludarabine-induced apoptosis in vitro, this finding suggests that
bfl-1 may be important for the extended survival of the leukaemic
cells in vivo.
Targeting bcl-2 family members is recognised as a promising
therapeutic strategy in B-CLL. bcl-2 antisense therapeutic
strategy has proven feasible without toxicity and is already in
clinical trials for B-CLL patients (O’Brien et al, 2005). Our results
suggest that an approach involving also the targeting of bfl-1
deserves further testing.
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Figure 4 siRNA-mediated targeting of bfl-1 in B-CLL cells. B-CLL cells from four in vitro fludarabine-resistant and bfl-1 high-expressing cases (CLL-24,
CLL-32, CLL-27 and CLL-33) were transfected with bfl-1-specific siRNA, control siRNA oligo or were not transfected. At 24h cells were harvested, mRNA
was isolated and analysed for bfl-1 mRNA expression by RT–PCR. (A) At the same time apoptosis was quantified using AnnexinV staining to quantify
apoptosis. (B) Data show one representative experiment out of two.
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